Möchten Sie immer auf dem neuesten Stand bleiben?

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)To broaden signal-finding activities for izicopan in...

- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - ...

Biopharmaceutical company, Renexxion Ireland, is granted its sixth U.S. patent for naronapride as it continues to advance new therapies for GI disorders.

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from...

FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026HREC Approval Received for Next-Generation Bispecific NAV-242 to Initiate First-in-Human Phase 1...

MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today...

- Data is from comprehensive review of hospital charges and all-payer claims over five years -  - Preventable complications such as amputation and conduit infection increased initial hospital charges...

NDT Pharmaceuticals’ Wholly Owned Subsidiary Good Salt Life, Inc. Advances Toward Key Regulatory Milestones for Clean Republic® Multipurpose Disinfectant

Austin, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Made In Cookware, the premium cookware brand trusted by professional chefs and home cooks alike, today announced a new partnership with Light Labs, an...

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improve